Revolution Medicines, Inc.
$143.09
▼
-3.9%
2026-04-22 10:12:13
www.revmed.com
NMS: RVMD
Explore Revolution Medicines, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$30.24 B
Current Price
$143.09
52W High / Low
$155.7 / $34
Stock P/E
—
Book Value
$8.28
Dividend Yield
—
ROCE
-57.28%
ROE
-58.07%
Face Value
—
EPS
$-5.95
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
883
Beta
1.01
Debt / Equity
26.18
Current Ratio
7.14
Quick Ratio
7.14
Forward P/E
-14.32
Price / Sales
—
Enterprise Value
$17.51 B
EV / EBITDA
-14.91
EV / Revenue
—
Rating
Strong Buy
Target Price
$133.7
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Calidi Biotherapeutics, Inc. | $0.25 | — | $3 M | — | -410.2% | -7.01% | $19.2 / $0.21 | $0.51 |
| 2. | Olema Pharmaceuticals, Inc. | $16.58 | — | $1.47 B | — | -37.1% | -36.61% | $36.26 / $3.89 | $5.88 |
| 3. | NeuroSense Therapeutics Ltd. | $0.71 | — | $25.1 M | — | -383.35% | -21.75% | $2.6 / $0.63 | $-0.05 |
| 4. | CytoMed Therapeutics Limited | $1.02 | — | $12.07 M | — | -33.09% | -50.28% | $3.68 / $0.73 | $0.43 |
| 5. | SeaStar Medical Holding Corporation | $4.63 | — | $16.77 M | — | -116.89% | -2.95% | $13.4 / $2.07 | $2.71 |
| 6. | Black Diamond Therapeutics, Inc. | $3.05 | 7.84 | $175.3 M | — | 15.61% | 22.88% | $4.94 / $1.31 | $1.96 |
| 7. | AEON Biopharma, Inc. | $1.07 | — | $25.81 M | — | 252.78% | -46.26% | $1.45 / $0.38 | $-4.54 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -361.63 M | -315.27 M | -264.71 M | -240.76 M | -216.31 M | — |
| Net Profit | -364.89 M | -305.21 M | -247.79 M | -213.42 M | -194.57 M | — |
| EPS in Rs | -1.84 | -1.54 | -1.25 | -1.08 | -0.98 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 11.58 M | 35.38 M |
| Operating Profit | -1.18 B | -689.52 M | -487.19 M | -258.28 M |
| Net Profit | -1.13 B | -600.09 M | -436.37 M | -248.71 M |
| EPS in Rs | -5.71 | -3.03 | -2.2 | -1.25 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 2.35 B | 2.56 B | 2.06 B | 811.93 M |
| Total Liabilities | 723.21 M | 293.1 M | 235.51 M | 126.74 M |
| Equity | 1.63 B | 2.27 B | 1.83 B | 685.19 M |
| Current Assets | 2.08 B | 2.33 B | 1.88 B | 660.18 M |
| Current Liabilities | 290.42 M | 163.91 M | 143.85 M | 61.98 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -897.74 M | -557.44 M | -350.57 M | -224.4 M |
| Investing CF | 118.06 M | -554.39 M | -342.6 M | -24.12 M |
| Financing CF | 621.52 M | 959.41 M | 1.23 B | 301.43 M |
| Free CF | -913.73 M | -567.74 M | -358.3 M | -235.22 M |
| Capex | -15.99 M | -10.31 M | -7.73 M | -10.82 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | -100% | -67.27% | — |
| Earnings Growth % | -88.52% | -37.52% | -75.46% | — |
| Profit Margin % | — | — | -3768.28% | -702.95% |
| Operating Margin % | — | — | -4207.12% | -730.01% |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | -3718.32% | -702.72% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.